3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
49
Nivolumab
22
Cyclophosphamide
20
fludarabine
13
Paclitaxel
9
Ipilimumab
9
atezolizumab
8
aldesleukin
8
Specimen Handling
8
Interleukin-2
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Docetaxel
6
Biopsy
6
cemiplimab
5
fludarabine phosphate
4
durvalumab
4
Taxes
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
poly ICLC
3
epacadostat
3
X-Rays
3
Leucovorin
3
Injections
3
Immunoglobulin G
3
Filgrastim
3
Cisplatin
3
CTLA-4 Antigen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled